What do systematic reviews say?

Silodosin vs naftopidil

Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.41, 2.56]
  5 studies · 808 participants
  Low

Silodosin vs naftopidil

Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 5.93 [2.16, 16.29]
  4 studies · 405 participants
  Moderate

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Moderate

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs alfuzosin

Silodosin showed no clear difference in cardiovascular adverse events compared with alfuzosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.36, 1.24]
  1 study · 60 participants
  Low

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 820 participants
  Moderate

Silodosin vs alfuzosin

Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 37.21 [5.32, 260.07]
  1 study · 95 participants
  Moderate

Silodosin vs placebo

Silodosin showed no clear difference in treatment withdrawal due to any reason compared with placebo (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.08 [0.7, 1.66]
  3 studies · 1703 participants
  Low

Silodosin vs placebo

It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.28 [0.67, 2.45]
  4 studies · 1967 participants
  Very low

Silodosin vs placebo

Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 26.07 [12.36, 54.97]
  4 studies · 1967 participants
  Moderate

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1708 participants
  Low

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1707 participants
  Low

Silodosin vs tamsulosin

It is very uncertain whether silodosin changes treatment withdrawal due to any reason compared with tamsulosin (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.62, 1.69]
  10 studies · 1573 participants
  Very low

Silodosin vs tamsulosin

Silodosin showed no clear difference in cardiovascular adverse events compared with tamsulosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.53, 1.12]
  11 studies · 1955 participants
  Low

LOD 4‐5 vs 2 or fewer punctures

The review found no eligible studies for this question.

• Ovarian surgery for symptom relief in women with polycystic ovary syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

LOD of one ovary (unilateral) vs LOD of both ovaries (bilateral)

It is very uncertain whether LOD of one ovary (unilateral) changes miscarriage compared with LOD of both ovaries (bilateral) (very low certainty).

• Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome 2020 · Cochrane Headline outcomes only
  Peto OR 1.02 [0.31, 3.33]
  2 studies · 131 participants
  Very low

LOD of one ovary (unilateral) vs LOD of both ovaries (bilateral)

The review found no eligible studies for this question.

• Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

LOD of one ovary (unilateral) vs LOD of both ovaries (bilateral)

It is very uncertain whether LOD of one ovary (unilateral) changes live birth compared with LOD of both ovaries (bilateral) (very low certainty).

• Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome 2020 · Cochrane Headline outcomes only
  OR 0.83 [0.24, 2.78]
  1 study · 44 participants
  Very low

LOD of one ovary (unilateral) vs LOD of both ovaries (bilateral)

The review found no eligible studies for this question.

• Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found